secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001213900-25-074355
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal reports Q2 net loss $3.7M, cash $5.6M; plans tecarfarin trial in ESKD dialysis patients
--------------------------------------------------------------------------------

- Net loss of $3.7M for Q2 2025 versus $2.4M in Q2 2024; G&A increased to $2.7M from $1.2M.
- Cash and equivalents $5.6M at June 30, 2025, down from $10.0M at December 31, 2024.
- Plans to initiate clinical trial of tecarfarin in ESKD patients transitioning to dialysis; site activation expected later in 2025.
- Completed technical transfer and cGMP manufacturing of tecarfarin drug substance at a U.S. CDMO site.
- Added to Russell 3000E and Russell Microcap indexes effective June 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025074355/0001213900-25-074355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025074355/ea0252643-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-074355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer